Drug Development Targeting the Metabolic Nuclear Receptors: Recent Advances
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 1 June 2024 | Viewed by 193
Special Issue Editors
Interests: medicinal chemistry; chemical biology; natural products chemistry; drug discovery; anticancer agent; neurodegenerative disease therapeutics; metabolic disease therapeutics
Special Issues, Collections and Topics in MDPI journals
Interests: natural product; isolation; structure identification; physicochemical properties; bioactivity; structure-activity relationship; mechanism
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The metabolic nuclear receptors (NRs) consist of a subset of NR superfamily transcription factors. The activity of many NRs is modulated by lipophilic structurally diverse small molecules as internal ligands. Metabolic NR ligands not only serve biological studies, and are also applicable to the prevention or therapy of metabolic diseases e.g. insulin resistance and type II diabetes, hyperlipidemia and atherosclerosis, and more recently, non-alcohol fatty liver disease (NAFL) and non-alcohol steatohepatisis (NASH). The modulation of metabolic NRs even benefits the improvement of non-metabolic diseases such as liver, kidney or digestive tract diseases, cancer, viral infection, among others. This metabolic NR special issue aims to reflect the current status and recent progress in the chemical and/or pharmacological studies of natural and unnatural NR ligands, with an emphasis on the drug discovery and development efforts for various diseases through targeting different metabolic NRs.
Prof. Dr. Weishuo Fang
Prof. Dr. Haixia Chen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nuclear receptor
- metabolic diseases
- type II diabetes
- NASH
- hyperlipidemia
